Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease.

RMD Open
Mark KacarSinisa Savic

Abstract

This clinical case series describes our experience with the use of Janus kinase 1/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still's disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome. All patients suffered from disease non-responsive to conventional Disease-modifying antirheumatic drugs (DMARDs) as well as biological therapies including interleukin (IL)-1 and IL-6 blockade, relying instead on high daily doses of prednisolone. We also report the first case of Pneumocystis jirovecii infection following baricitinib use.

References

Nov 20, 2015·Seminars in Arthritis and Rheumatism·Katharina HofheinzBernhard Manger
Mar 31, 2016·The New England Journal of Medicine·Mark C GenoveseJosef S Smolen
Jun 24, 2016·Acta Haematologica·Ofir Wolach, Richard Stone
Feb 16, 2017·The New England Journal of Medicine·Peter C TaylorYoshiya Tanaka
Apr 13, 2018·The Journal of Clinical Investigation·Gina A Montealegre SanchezRaphaela Goldbach-Mansky
Feb 23, 2020·Annals of the Rheumatic Diseases·Qiongyi HuChengde Yang

❮ Previous
Next ❯

Citations

Feb 7, 2021·Nature Reviews. Rheumatology·Dennis McGonagleCharlie Bridgewood
Mar 7, 2021·Journal of Clinical Medicine·Stylianos TomarasEugen Feist
Jun 16, 2021·Expert Opinion on Biological Therapy·Yuko Kaneko, Tsutomu Takeuchi

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
ESR

Related Concepts

Related Feeds

Adult-Onset Still's Disease

Adult-onset Still's disease (AOSD) is a form of Still's disease, a rare systemic autoinflammatory disease characterized by the classic triad of persistent high spiking fevers, joint pain, and a distinctive salmon-colored bumpy rash. Discover the latest research on AOSD here.